Product status notice
A chemical reagent intended solely for laboratory research (Research Use Only). It is not a medicinal product, dietary supplement or foodstuff. It is not intended for use in humans or animals. Sales are limited to registered research institutions and laboratories.
MK-2866 (Ostarine, Enobosarm, GTx-024, S-22) is a non-steroidal selective androgen receptor modulator (SARM) of the arylpropionamide class – a sister compound of S4 (Andarine), derived from the same research line that began with modifications of the antiandrogen bicalutamide. The compound was developed and characterised at GTx Inc. by the team of James Dalton and Duane Miller (Memphis) and then taken through the most extensive clinical programme of any SARM – phases I, II and III in age-related sarcopenia and cancer cachexia.
This makes Ostarine the most clinically studied compound in the entire SARM class and a natural reference reagent in comparative studies of androgen receptor (AR) tissue selectivity.
In the Pro-Body catalogue, Ostarine belongs to the SARMs category of the Endogenic line. This reagent is supplied in the Endogenic line as an oral solution in a 30 ml dropper bottle (mg/ml concentration declared in the batch COA). The dropper solution format suits laboratory research protocols using working concentrations in vitro on AR-expressing cell lines and in vivo in rodent models – the dropper makes it easy to measure repeatable volumes of a solution of known mg/ml concentration without weighing powder for each test.
Chemically, MK-2866 differs from steroidal androgens in lacking the cyclic steroid core – it is a non-steroidal AR ligand with a partial agonist profile.
The central axis of the mechanism is tissue selectivity: the compound binds the androgen receptor with high affinity (Ki ~3.8 nM) and induces receptor conformations leading to an anabolic transcriptional response in skeletal muscle and bone that is much stronger than in glandular tissues (prostate, seminal vesicles). Of the entire SARM family, Ostarine shows the highest tissue selectivity relative to the prostate, together with the lowest suppression of the HPG (hypothalamic-pituitary-gonadal) axis – which historically made it GTx’s leading clinical candidate. Purity verified by HPLC ≥98%, identity confirmed by mass spectrometry, COA available for each batch.
Regulatory status
MK-2866 (Ostarine) is the most extensively clinically studied SARM – the GTx programme covered phases I–III in sarcopenia and cancer cachexia. Nevertheless, the compound has not been authorised as a medicine in any jurisdiction: the phase III trials (POWER trials) in cancer cachexia did not meet the required primary endpoint to the satisfaction of the regulatory authorities.
It has no EMA, FDA or EFSA authorisation as a dietary supplement ingredient. MK-2866 has been on the WADA Prohibited List (category S1.2 – other anabolic agents, SARMs) since 2008 and is prohibited at all times. The FDA has issued Warning Letters about products containing SARMs. Presenting the product as a “SARM for body recomposition”, a “lean mass agent” or “muscle protection for athletes” is contrary to the Research Use Only framework.